An Analysis Of Sabra Health Care REIT Inc. (SBRA)’s Weekly Performance


As of Friday close, Sabra Health Care REIT Inc.’s (NASDAQ:SBRA) stock was down -$0.37, moving down -3.35 percent to $10.69. The average number of shares traded per day over the past five days has been 2,739,740 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.51 fall in that time frame. In the last twenty days, the average volume was 2,454,040, while in the previous 50 days, it was 1,917,196.

Since last month, SBRA stock retreated -17.71%. Shares of the company fell to $10.64 on 03/17/23, the lowest level in the past month. A 52-week high of $16.60 was reached on 02/02/23 after having rallying from a 52-week low of $10.90. Since the beginning of this year, SBRA’s stock price has dropped by -14.00% or -$1.74, and marked a new high 11 times. However, the stock has declined by -35.60% since its 52-week high.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Valuation Metrics

The stock’s beta is 1.32. Besides these, the trailing price-to-sales (P/S) ratio of 4.09, the price-to-book (PB) ratio of 0.81.

The latest dividend of $0.30 per share was paid out, remained unchanged from last year’s $0.30. On Wednesday May 6 2020, a $0.15 dividend decrease was announced.

Financial Health

According to company report, the long-term debt-to-equity ratio for the quarter ending December 30 was 0.82, and the total debt-to-equity ratio was 0.82. On the profitability front, the trailing twelve-month gross margin is 77.10% percent. In the year ended December 30, operating margins totaled 6.00%. Based on annual data, SBRA earned $140.66 million in gross profit and brought in $624.81 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 0.60%. Return on equity (ROE) for the past 12 months was -2.40%.

In Sabra Health Care REIT Inc.’s quarter-end financial report for December 30, it reported total debt of $49.23 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. SBRA’s revenue rose 17.78% to $140.76 million during the quarter, while net income inched up to $164.99 million. While analysts expected Sabra Health Care REIT Inc. to report $0.12 quarterly earnings, the actual figure was -$0.37 per share, beating the consensus estimate by -408.30%.

Technical Picture

This quick technical analysis looks at Sabra Health Care REIT Inc.’s (SBRA) price momentum. With a historical volatility rate of 32.81%, the RSI 9-day stood at 22.61% on 17 March.

With respect to its five-day moving average, the current Sabra Health Care REIT Inc. price is down by -4.55% percent or -$0.51. At present, SBRA shares trade -18.08% below its 20-day simple moving average and -16.94% percent below its 100-day simple moving average. However, the stock is currently trading approximately -18.40% below its SMA50 and -23.86% below its SMA200.

Stochastic coefficient K was 12.59% and Stochastic coefficient D was 18.54%, while ATR was 0.38. Given the Stochastic reading of 3.12% for the 14-day period, the RSI (14) reading has been calculated as 25.91%. As of today, the MACD Oscillator reading stands at -0.32, while the 14-day reading stands at -0.53.

Analyst Ratings

Sabra Health Care REIT Inc. downgraded its rating on Sabra Health Care REIT Inc. (NASDAQ: SBRA) to a Mkt perform in a note to investors on December 13, 2022. The analysts firm previously had a Mkt outperform rating on the stock.


Please enter your comment!
Please enter your name here